Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

NCT02939274 is registered in ClinicalTrials.gov with Rogers Sciences Inc. as lead sponsor.

NCT NCT02939274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02939274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
Lead sponsor
Rogers Sciences Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
December 31, 2019
Enrollment
15 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer